Nonintervention Matches Ibuprofen for Preterm PDA at Two Years
This prespecified two-year follow-up of a randomized trial offers pediatric pharmacists rare randomized long-term data suggesting that withholding oral ibuprofen for hemodynamically significant patent ductus arteriosus does not compromise growth or neurodevelopment.
📅 Journal publication: Jun 29, 2026·Last updated: Jul 11, 2026
Is early PDA closure in preemies really necessary?
Managing patent ductus arteriosus (PDA) in premature infants is controversial, and understanding long-term outcomes aids in treatment decisions. No significant differences in growth or neurodevelopmental impairment at 2 years between nonintervention (NI) and ibuprofen (IBU) groups; some spontaneous closures of PDA occurred. The study suggests nonintervention is as safe as ibuprofen treatment for PDA in preterm infants, with similar long-term outcomes, questioning the need for routine pharmacologic closure. Nonintervention is a clinically safe option for managing PDA in preterm infants.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Sung SI, Yang M, Ahn SY, Chang YS, Park WS
Citation:Sung SI, Yang M, Ahn SY, et al. Two-Year Outcomes of a Randomized Controlled Trial of Nonintervention Versus Oral Ibuprofen for Patent Ductus Arteriosus in Premature Infants. Journal of Korean medical science. 2026;41(25):e182. doi:10.3346/jkms.2026.41.e182